CRESCENT BIOPHARMA INC.
COM · CUSIP 38000Q201
3
institutional holders
+1 vs Q4 2025
835.9k
shares reported held*
$15.4mreported value*
1 new
1 added
0 reduced
0 sold out
net bought ≈ $8.5m (+461.4k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $18.37.
Trends to Q1 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2025 | 2 |
| Q1 2026 | 3 |
Biggest buyers
| Boxer Capital Management, LLC | New | +453.7k |
| Quadrature Capital Ltd | Added | +7.7k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| 1Globe Capital LLC 13G · passive investor +3.9 pts · filed 2025-10-14 | 10.3% |
| FMR LLC 13G · institution new · filed 2025-07-08 | 10.2% |
| Venrock Healthcare Capital Partners III, L.P. 13G · passive investor new · filed 2025-06-23 | 9.9% |
| BALYASNY ASSET MANAGEMENT L.P. 13G · institution +0.5 pts · filed 2026-08-14 | 6.0% |
Holders, Q1 2026
| Manager | Shares | Change |
|---|---|---|
| Boxer Capital Management, LLC 1.09% of their portfolio | 453.7k $8.3m | New |
| Remedium Capital Partners, LLC 2.36% of their portfolio | 361.2k $6.6m | Unchanged |
| Quadrature Capital Ltd 0.00% of their portfolio | 20.9k $384.2k | Added +7.7k |